CDK2 and breast carcinoma: Many of the proposed resistance mechanisms such as Rb loss or CDK2 activation are not easily amenable to targeted therapeutic interventions; however, the PI3K pathway activation in breast cancer has been successfully targeted with small molecule inhibitors.